Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma

Patients diagnosed with B-cell non-Hodgkin lymphoma (B-NHL), particularly if recently treated with anti-CD20 antibodies, are at risk of severe COVID-19 disease. Because studies evaluating humoral response to COVID-19 vaccine in these patients are lacking, recommendations regarding vaccination strate...

Descripción completa

Detalles Bibliográficos
Autores principales: Perry, C., Luttwak, E., Balaban, R., Shefer, G., Morales, M. M., Aharon, A., Tabib, Y., Cohen, Y. C., Benyamini, N., Beyar-Katz, O., Neaman, M., Vitkon, R., Keren-Khadmy, N., Levin, M., Herishanu, Y., Avivi, I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362658/
https://www.ncbi.nlm.nih.gov/pubmed/34387648
http://dx.doi.org/10.1182/bloodadvances.2021005094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362658/
https://www.ncbi.nlm.nih.gov/pubmed/34387648
http://dx.doi.org/10.1182/bloodadvances.2021005094

Ejemplares similares